Inhibrx Biosciences (INBX) Invested Capital: 2023-2025
Historic Invested Capital for Inhibrx Biosciences (INBX) over the last 2 years, with Sep 2025 value amounting to $136.7 million.
- Inhibrx Biosciences' Invested Capital fell 23.38% to $136.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $136.7 million, marking a year-over-year decrease of 23.38%. This contributed to the annual value of $133.6 million for FY2024, which is 207.07% up from last year.
- Inhibrx Biosciences' Invested Capital amounted to $136.7 million in Q3 2025, which was down 18.52% from $167.8 million recorded in Q2 2025.
- Inhibrx Biosciences' Invested Capital's 5-year high stood at $219.4 million during Q2 2024, with a 5-year trough of $43.5 million in Q4 2023.
- Its 3-year average for Invested Capital is $153.2 million, with a median of $167.8 million in 2025.
- Per our database at Business Quant, Inhibrx Biosciences' Invested Capital skyrocketed by 207.07% in 2024 and then declined by 23.49% in 2025.
- Quarterly analysis of 3 years shows Inhibrx Biosciences' Invested Capital stood at $43.5 million in 2023, then soared by 207.07% to $133.6 million in 2024, then fell by 23.38% to $136.7 million in 2025.
- Its last three reported values are $136.7 million in Q3 2025, $167.8 million for Q2 2025, and $193.1 million during Q1 2025.